Last reviewed · How we verify
NCT06997458: LOLA-PROJECT
Liquid BiOpsy, Lung and Colon Cancer in AndaluciA
trial testing xF Tempus assay in Non Small Cell Lung Cancer (NSCLC) in 500 participants. Enrolling by invitation.
30 July 2025
Quick facts
| Lead sponsor | Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental |
|---|---|
| Status | ENROLLING BY INVITATION |
| Study type | OBSERVATIONAL |
| Enrollment | 500 |
| Start date | 1 August 2024 |
| Primary completion | 30 July 2025 |
| Estimated completion | 30 July 2026 |
| Sites | 1 location across Spain |
Drugs / interventions tested
- xF Tempus assay
Conditions studied
- Non Small Cell Lung Cancer (NSCLC) — all drugs for Non Small Cell Lung Cancer (NSCLC) →
- Colorectal Cancer (CRC) — all drugs for Colorectal Cancer (CRC) →
Sponsor
Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental
Who can join
18 and older, any sex, with Non Small Cell Lung Cancer (NSCLC) or Colorectal Cancer (CRC). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The objective of the LOLA Project is to analyse the impact of adopting xF liquid biopsy panel, in the real world of the Andalusian Health Public System in terms of impact on clinical practice and cost through the assessment of clinical impact, duration of turnaround time (TAT) of xF test vs standard of care and the analysis of resource utilisation.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06997458
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Non Small Cell Lung Cancer (NSCLC)
Currently open trials in the same condition.
- NCT07206498 — A Study to Evaluate Safety and Efficacy of WSD0922-FU Combo With Osimertinib for NSCLC · Phase 1, PHASE2 · recruiting
- NCT06889467 — Liquid Biopsy Assay of EBUS-TBNA Supernatant Fluid for Diagnosing Lung Cancer · recruiting
Other Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental trials
Trials by the same sponsor.
- NCT06722443 — Impact of Nutritional Intervention With Probiotics and Prebiotics on Obesity. · NA · enrolling by invitation
- NCT06639126 — Intervention Study Focused on the Intestinal Microbiome to Evaluate the Impact of a Wild Thyme Extract (Thymus Serpyllum · NA · enrolling by invitation
- NCT05628818 — Noninvasive Transcranial Direct Current Stimulation to Improve Executive Functions in Stroke Patients. MODUL-EXE Clinica · NA · unknown
- NCT04894357 — Impact of V106I on Resistance to Doravirine · unknown
- NCT06392633 — SURGERY VS BOTULINUM TOXIN ON QUALITY OF LIFE IN STROKE PATIENTS: RANDOMIZED TRIAL · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06997458 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental
- Last refreshed: 30 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06997458.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing